Tofacitnib for the Treatment of Alopecia Areata and Variants

This study is an open-label pilot study. Participants will be treated with oral tofacitinib
for a maximum of 5 months. Participants will be evaluated at 3 months after completion of
therapy to evaluate for durability of response, late response and/or late adverse effects.

Inclusion Criteria:

- Age >= 18 years old

- Diagnosis of alopecia areata with >50% scalp involvement, alopecia totalis, or
alopecia universalis

- Hair loss present for at least 6 months

- No treatment for alopecia areata in past 2 months

- No evidence of hair regrowth

- Females of childbearing potential must use birth control while taking the medication
and there must be a negative pregnancy test documented prior to starting the
medication

Exclusion Criteria:

- Age <18 years old

- Patients have received treatment known to affect alopecia areata within 2 months of
enrolling in the study

- Patients with a history of malignancy (except history of successfully treated basal
cell or squamous cell carcinoma of the skin)

- Patients known to be HIV or hepatitis B or C positive

- Patients with positive tuberculin skin test or positive QuantiFERON TB test

- Patients with leukopenia or anemia

- Patients with renal or hepatic impairment

- Patients with peptic ulcer disease

- Patients taking immunosuppressive medications, including but not limited to
prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus,
cyclosporine, or TNH-alpha inhibitors

- Women of childbearing potential who are unable or unwilling to use birth control
while taking the medication

- Women who are pregnant or nursing